HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schirmbeck, R. Articles by Lu, M. Search for Related Content PubMed PubMed Citation Articles by Schirmbeck, R. Articles by Lu, M.

Targeting Murine Immune Responses to Selected T Cell- or Antibody-Defined Determinants of the Hepatitis B Surface Antigen by Plasmid DNA Vaccines Encoding Chimeric Antigen¹

Reinhold Schirmbeck^2,*, Xin Zheng, Michael Roggendorf, Michael Geissler, Francis V. Chisari, Jörg Reimann^* and Mengji Lu

^* Institute of Medical Microbiology and Immunology, University of Ulm, Ulm, Germany; Institute of Virology, University of Essen, Essen, Germany; Department of Internal Medicine II, University Hospital of Freiburg, Freiburg, Germany; and Division of Experimental Pathology, The Scripps Research Institute, La Jolla, CA 92037

By exchanging sequences from the middle-surface (MS) and small-surface (S) Ag of hepatitis B virus (HBV) with corresponding sequences of the MS Ag of woodchuck hepatitis virus, we constructed chimeric MS variants. Using these constructs as DNA vaccines in mice, we selectively primed highly specific (non-cross-reactive) Ab responses to pre-S2 of the HBV MS Ag and the "a" determinant of the HBV S Ag, as well as L^d- or K^b-restricted CTL responses to HBV S epitopes. In transgenic mice that constitutively express large amounts of HBV surface Ag in the liver we could successfully suppress serum antigenemia (but not Ag production in the liver) by adoptive transfer of anti-pre-S2 or anti-"a" immunity but not CTL immunity. DNA vaccines greatly facilitate construction of chimeric fusion Ags that efficiently prime specific, high-affinity Ab and CTL responses. Such vaccines, in which sequences of an Ag of interest are exchanged between different but related viruses, are interesting tools for focusing humoral or cellular immunity on selected antigenic determinants and elucidating their biological role.

This article has been cited by other articles:

				X. Li, X. Yang, Y. Jiang, and J. Liu A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice Int. Immunol., October 1, 2005; 17(10): 1293 - 1302. [Abstract] [Full Text] [PDF]

				A. Thermet, M. Robaczewska, C. Rollier, O. Hantz, C. Trepo, G. Deleage, and L. Cova Identification of Antigenic Regions of Duck Hepatitis B Virus Core Protein with Antibodies Elicited by DNA Immunization and Chronic Infection J. Virol., February 15, 2004; 78(4): 1945 - 1953. [Abstract] [Full Text] [PDF]

				E. Chun, J. Lee, H. S. Cheong, and K.-Y. Lee Tumor Eradication by Hepatitis B Virus X Antigen-Specific CD8+ T Cells in Xenografted Nude Mice J. Immunol., February 1, 2003; 170(3): 1183 - 1190. [Abstract] [Full Text] [PDF]

				P. Riedl, S. El Kholy, J. Reimann, and R. Schirmbeck Priming Biologically Active Antibody Responses Against an Isolated, Conformational Viral Epitope by DNA Vaccination J. Immunol., August 1, 2002; 169(3): 1251 - 1260. [Abstract] [Full Text] [PDF]